Morgan Stanley Neurocrine Biosciences Inc Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Morgan Stanley holds 1,349,381 shares of NBIX stock, worth $185 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,349,381

Previous 1,544,869 12.65%

Holding current value

$185 Million

Previous $213 Million 26.95%

% of portfolio

0.01%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $22.4 Million - $29.9 Million	-195,488 Reduced 12.65%	1,349,381 $155 Million
Q2 2024 Oct 17, 2024	SELL	$130.86 - $143.19 $68.1 Million - $74.6 Million	-520,767 Reduced 25.21%	1,544,869 $213 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $68.1 Million - $74.6 Million	-520,767 Reduced 25.21%	1,544,869 $213 Million
Q1 2024 Oct 17, 2024	BUY	$130.4 - $143.74 $67.9 Million - $74.9 Million	520,767 Added 33.71%	2,065,636 $285 Million
Q1 2024 Aug 16, 2024	SELL	$130.4 - $143.74 $34 Million - $37.5 Million	-260,658 Reduced 11.2%	2,065,636 $285 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $34 Million - $37.5 Million	-260,658 Reduced 11.2%	2,065,636 $285 Million
Q4 2023 Aug 16, 2024	BUY	$106.07 - $132.76 $82.9 Million - $104 Million	781,425 Added 50.58%	2,326,294 $307 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $42.7 Million - $53.4 Million	402,215 Added 20.9%	2,326,294 $307 Million
Q3 2023 Nov 15, 2023	BUY	$94.02 - $117.1 $5.27 Million - $6.56 Million	56,054 Added 3.0%	1,924,079 $216 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $19.1 Million - $22.4 Million	213,132 Added 12.88%	1,868,025 $176 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $37 Million - $48.4 Million	-393,192 Reduced 19.2%	1,654,893 $168 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $161 Million - $192 Million	1,511,307 Added 281.55%	2,048,085 $245 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $4.56 Million - $5.34 Million	49,503 Added 10.16%	536,778 $57 Million
Q2 2022 Oct 27, 2022	BUY	$75.79 - $100.07 $23.5 Million - $31.1 Million	310,448 Added 175.57%	487,275 $47.5 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $23.5 Million - $31.1 Million	310,448 Added 175.57%	487,275 $47.5 Million
Q1 2022 Oct 27, 2022	SELL	$72.45 - $94.81 $22.5 Million - $29.4 Million	-310,448 Reduced 63.71%	176,827 $16.6 Million
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $2.71 Million - $3.55 Million	37,462 Added 26.88%	176,827 $16.6 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $440,145 - $586,971	-5,526 Reduced 3.81%	139,365 $11.9 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $12.5 Million - $14.3 Million	144,891 New	144,891 $13.9 Million

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account